Australia's Rhythm Biosciences gains on cancer test collaboration

Rhythm Biosciences

10/12/2025 03:17

** Rhythm Biosciences RHY.AX rises as much as 5.2% to A$0.082; set for strongest trading session in more than a week

** Stock hits highest since December 3

** Medical diagnostics co enters collaboration with The Southern Hub Research Team, Royal Surrey NHS Foundation Trust to evaluate suitability of ColoSTAT for potential use in bowel cancer screening pathway in England

** ColoSTAT test is a blood-based test used to detect colorectal cancer

** YTD, RHY down ~6%

 (Reporting by Aamir Sheik Khalid in Bengaluru)

 ((Aamir.SheikKhalid@thomsonreuters.com))